Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer

Noda, Kiichiro; Teshima, Kensaku; Tekeuti, K; Hasegawa, Kazuo; Inoue, Kinya; Yamashita, K.; Sawaragi, I; Nakajima, Tokuro; Takashima, E; Ikeuchi, M; Sekiba, K; Okuda, Hiroyuki; Ichijo, Motohiko; Saito, Toshikatsu; Ozawa, Mitsuru; Tamura, Hiroyuki; Chihara, Tsutomu; Kuzuya, Kazuo; Ozaki, Masami; Inagaki, Minoru; Tominaga, Suketami

doi:10.1016/0090-8258(89)90081-4

Cited by 13 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because Picibanil causes immunologic up-regulation because of the antigenicity of the streptococci, it was developed initially for use in head and neck cancers. Although numerous clinical trials failed to demonstrate any antitumor effects, 13 2 important findings did emerge. First, it became apparent that when injected into the pleural and peritoneal cavities to treat malignant effusions, Picibanil has sclerosing properties 14 .…”

Section: Discussionmentioning

confidence: 99%

Treatment of Lymphangiomas in Children: An Update of Picibanil (OK‐432) Sclerotherapy

Greinwald

Burke

Sato

et al. 1999

Otolaryngol.--head neck surg.

111

View full text Add to dashboard Cite

Picibanil (OK-432) is a sclerosing agent derived from a low-virulence strain of Streptococcus pyogenes that induces regression of macrocystic lymphangiomas. This report describes a prospective, nonrandomized trial to evaluate the efficacy of Picibanil in the treatment of 13 affected children ranging in age from 1 to 94 months. On average, 4.1 fluoroscopically guided intracystic injections were performed per child, with an average total dose of 0.56 mg of Picibanil. As judged by physical examination and radiographic studies, 5 children (42%) showed a complete or substantial response, and 2 children (16%) showed an intermediate response. No response was seen in 5 children (42%), 2 of whom had massive craniofacial lymphangioma. Factors that contribute to failure with Picibanil sclerotherapy are the presence of a significant microcystic component to the lesion, massive craniofacial involvement, and previous surgical resection. Macrocystic lymphangiomas of the infratemporal fossa or cervical area have the best response to therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Lymphangiomas in Children: An Update of Picibanil (OK‐432) Sclerotherapy

Greinwald

Burke

Sato

et al. 1999

Otolaryngol.--head neck surg.

111

View full text Add to dashboard Cite

show abstract

“…Various nonspecific immune system modulators, including interferon α, interleukin 12, extract derived from agaricus blazei murill kyowa, mycobacterium tuberculosis (Z-100) or streptococcal preparations (OK-432) as well as sizofiran and thymopentin or cornyebacterium parvum have been studied for cervical cancer [ 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 ]. All agents affect the immune system in a general way at different levels.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Immunotherapy for Cervical Cancer—A Systematic Review of Clinical Trials

Schmidt

Battista

Schmidt

et al. 2022

Cancers

View full text Add to dashboard Cite

Purpose: To systematically review the current body of evidence on the efficacy and safety of immunotherapy for cervical cancer (CC). Material and Methods: Medline, the Cochrane Central Register of Controlled Trials and Web of Science were searched for prospective trials assessing immunotherapy in CC patients in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Full-text articles in English and German reporting outcomes of survival, response rates or safety were eligible. Results: Of 4655 screened studies, 51 were included (immune checkpoint inhibitors (ICI) n=20; therapeutic vaccines n = 25; adoptive cell transfer therapy n=9). Of these, one qualified as a phase III randomized controlled trial and demonstrated increased overall survival following treatment with pembrolizumab, chemotherapy and bevacizumab. A minority of studies included a control group (n = 7) or more than 50 patients (n = 15). Overall, response rates were low to moderate. No response to ICIs was seen in PD-L1 negative patients. However, few remarkable results were achieved in heavily pretreated patients. There were no safety concerns in any of the included studies. Conclusion: Strong evidence on the efficacy of strategies to treat recurrent or metastatic cervical cancer is currently limited to pembrolizumab in combination with chemotherapy and bevacizumab, which substantiates an urgent need for large confirmatory trials on alternative immunotherapies. Overall, there is sound evidence on the safety of immunotherapy in CC.

show abstract

“…Noda et a/. (43) reported in a randomized study that the streptococcal preparation, OK-432 demonstrated a significant survival benefit in stage II disease, but these findings were in subset analysis only.…”

Section: Biologic Response Modifiersmentioning

confidence: 97%

Radiotherapeutic management in carcinoma of the uterine cervix: current status

Kim

1993

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Despite refinement in the delivery of external radiation and brachytherapy, there has been little improvement in the survival rate of patients with invasive cancer of the uterine cervix in recent years. With advancing stage disease, there is an increase in both local failure and distant metastases. Although recent efforts to improve local control for late stage disease have been encouraging, research efforts should be directed to the identification of new active drugs for radiation sensitization and systemic therapy. Also, due to early detection, therapeutic investigations should focus on the high-risk subsets of patients with early stage disease.

show abstract

Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer

Cited by 13 publications

References 16 publications

Treatment of Lymphangiomas in Children: An Update of Picibanil (OK‐432) Sclerotherapy

Treatment of Lymphangiomas in Children: An Update of Picibanil (OK‐432) Sclerotherapy

Efficacy and Safety of Immunotherapy for Cervical Cancer—A Systematic Review of Clinical Trials

Radiotherapeutic management in carcinoma of the uterine cervix: current status

Contact Info

Product

Resources

About